Abstract
This article presents the recommendations and suggestions for future research of an American Academy of Neurology (AAN) practice guideline on the efficacy and safety of diseasemodifying therapies (DMTs) in multiple sclerosis (MS). The complete practice guideline and references e1 through e49, cited here, are available at links.lww.com/WNL/A458 and links.lww.com/WNL/A377, respectively. A companion article summarizes the systematic review findings and conclusions. This guideline, although not a formal update to the 2002 AAN guideline on DMTs, 1 replaces that earlier guideline.
In May 2015, the AAN guideline subcommittee convened a multidisciplinary panel to perform a systematic review and develop guideline recommendations regarding DMT for MS.
The systematic review was completed in November 2016; its methodology and results are described in a companion systematic review. 2 The panel developed recommendations, founded on the systematic review, concerning the starting, switching, and stopping of DMTs. This summary article focuses on the recommendations and does not include detailed analysis of the systematic review. Readers are urged to review the fulllength document (links.lww.com/WNL/A458) and accompanying tables (appendix e-5, links.lww.com/WNL/A376) for a fuller assessment of this guideline. 1 Much more than evidence must be considered when crafting practice recommendations. The evidence-based conclusions from the systematic review form the foundation of the AAN process, 3 but additional factors influence recommendation structure. Working in teams, the panel developed rationale statements for transparency in documenting the deductive logic justifying each recommendation. A rationale statement precedes each recommendation or recommendation set. Four premise types can support recommendations: evidence-based conclusions from the systematic review, generally accepted principles of care, strong evidence from related conditions, and deductive inferences from other premises. Recommendations must be supported by at least one premise.
When there is sufficient evidence to support an inference for an intervention's use (i.e., the balance of benefits and harms favors the intervention), the development panel assigns 1 of 3 recommendation designations: A, B, or C. Each designation corresponds to a helping verb that denotes the level of recommendation strength. Level A is the strongest recommendation level and is denoted by use of the helping verb must. These recommendations are rare, as they are based on high confidence in the evidence and require both a high magnitude of benefit and low risk. Level B corresponds to the helping verb should. Such recommendations are more common, as the requirements are less stringent but still based on the evidence and benefit−risk profile. Level C, which corresponds to the helping verb may, represents the lowest allowable recommendation level the AAN considers useful within the scope of clinical practice and can accommodate the highest degree of practice variation.
Other factors that need to be transparently and systematically considered when formulating recommendations include the relative value of the benefit compared with the risk, the feasibility of complying with the intervention (e.g., the intervention's availability), the intervention's cost, and the expected variation in patient preferences relative to the intervention's risks, burdens, and benefits.
The panel assigned levels of obligation (A, B, C, or U) to the recommendations, using a modified Delphi process that synthesizes all the preceding factors. The panelists provided their opinions concerning the importance of each factor through an online questionnaire, with statistical analysis of responses. All panelists voted online anonymously and independently on each recommendation in 3 voting rounds that involved precisely defined rules for consensus.
Each recommendation achieved consensus, was revised, or was not carried forward. In some cases, the panel reviewed, revised, and revoted on recommendations on the basis of public commentary and other input during the development process, reflecting the dynamic nature of this process.
For the systematic review, observational data did not drive conclusions, but the panel was not restricted in the recommendation phase from reflecting such data if appropriate in the process. In addition, longer-term safety and outcome data are often unavailable for newer agents, and guidelines cannot capture all the longitudinal changes in practice that may occur on the basis of clinical experience over time.
Suggestions for future research were also developed during the guideline development process. This guideline will be reassessed periodically for currency and will be updated in accordance with the most currently available AAN process manual.
Starting DMT: Recommendations
Starting: Recommendation 1
Rationale
Receiving the diagnosis of MS is a stressful life event. 4, 5 People receiving major diagnoses may not recall much of the information given to them at the time. 6 Providing information about DMT at a follow-up interaction is likely to allow a better understanding of these medications and their risks and benefits.
Statement 1
Clinicians should counsel people with newly diagnosed MS about specific treatment options with DMT at a dedicated treatment visit (Level B).
Starting: Recommendation 2 Rationale
Respecting patient preferences is an important component of care for chronic conditions. Because of the variety of DMTs available, evaluating patient preferences may improve acceptance of and adherence to DMT.
Statement 2a
Clinicians must ascertain and incorporate/review preferences in terms of safety, route of administration, lifestyle, cost, efficacy, common adverse effects (AEs), and tolerability in the choice of DMT in people with MS being considered for DMT (Level A).
Statement 2b
Clinicians must engage in an ongoing dialogue regarding treatment decisions throughout the disease course with people with MS (Level A).
Starting: Recommendation 3 Rationale
DMTs reduce but do not eliminate MS relapses and MRI activity. Educating people with MS about realistic expectations regarding DMT effects is important. 7 Clinicians should inform people with MS that they may still need symptomatic treatment in addition to DMT. 8 
Statement 3a
Clinicians should counsel people with MS that DMTs are prescribed to reduce relapses and new MRI lesion activity. DMTs are not prescribed for symptom improvement in people with MS (Level B).
Statement 3b
Clinicians must counsel people with MS on DMTs to notify the clinicians of new or worsening symptoms (Level A).
Starting: Recommendation 4 Rationale
Because DMT use requires commitment to ongoing therapy and an understanding of AEs, readiness to initiate DMT and factors causing reluctance may have an impact on adherence to DMT use.
Statement 4
Clinicians should evaluate readiness or reluctance to initiate DMT and counsel on its importance in people with MS who are candidates to initiate DMT (Level B).
Starting: Recommendation 5 Rationale
In people with MS, comorbid disease, such as depression, anxiety, and vascular risk factors, and adverse health behaviors (e.g., physical inactivity, smoking) are associated with worse outcomes. 9, 10 Addressing depression before initiating DMT may improve decision-making and adherence to DMT. Concomitant medications may have important interactions with DMTs.
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Statement 5
Clinicians should counsel about comorbid disease, adverse health behaviors, and potential interactions of the DMT with concomitant medications when people with MS initiate DMTs (Level B).
Starting: Recommendation 6 Rationale
Because DMT requires adherence to treatment to provide full efficacy, and because that adherence to treatment may be an issue for people with MS, 12,13 discussing adherence issues before initiating DMT is part of good clinical practice. Efforts to increase adherence may improve outcomes.
Statement 6a
Clinicians should evaluate barriers to adherence to DMT in people with MS (Level B).
Statement 6b
Clinicians should counsel on the importance of adherence to DMT when people with MS initiate DMTs (Level B).
Starting: Recommendation 7 Rationale
People presenting with a first demyelinating event who do not meet the 2010 International Criteria for MS are commonly encountered in clinical practice. Multiple prospective observational trials have consistently confirmed that people with a single clinical demyelinating event with 2 or more brain or spinal cord lesions remain at increased risk of a future MS diagnosis, with the highest risk incurred within 5 years of the initial event.
14-17 Evidence from multiple Class I and II trials confirms that DMTs are associated with a significant delay in second clinical relapse or new brain MRI-detected lesions in people with a first demyelinating event who are considered to be at high risk for MS on the basis of brain MRI-detected lesions. There is insufficient evidence concerning the comparative efficacy of specific DMTs for this purpose. Decisions concerning the selection of specific DMTs for people presenting with a first demyelinating event should abide by prescribing principles espoused in other recommendations. Individuals presenting with an incident demyelinating event who have no brain lesions are at low risk of a future MS diagnosis.
Statement 7a
Clinicians should discuss the benefits and risks of DMTs for people with a single clinical demyelinating event with 2 or more brain lesions that have imaging characteristics consistent with MS (Level B).
Statement 7b
After discussing the risks and benefits, clinicians should prescribe DMT to people with a single clinical demyelinating event and 2 or more brain lesions characteristic of MS who decide they want this therapy (Level B).
Starting: Recommendation 8 Rationale
The benefit of initiating DMT has not been studied in currently untreated people with clinically isolated syndromes (CIS) or relapsing forms of MS who have not had relapses in 2 or more years and do not have active new MRI lesion activity on recent imaging. In such people, it is unknown what the risk of harm is from initiating DMTs, including AEs, major AEs, and burden of taking a long-term medication, relative to the benefit of reducing relapse rate.
Statement 8
Clinicians may recommend serial imaging at least annually for the first 5 years and close follow-up rather than initiating DMT in people with CIS or relapsing forms of MS who are not on DMT, have not had relapses in the preceding 2 years, and do not have active new MRI lesion activity on recent imaging (Level C).
Starting: Recommendation 9 Rationale
Multiple studies of DMTs in people with relapsing forms of MS who have had recent relapses or MRI activity or both have shown benefit of DMT in terms of reducing relapses and reducing MRI activity. This includes people with a single clinical episode who meet 2010 International Criteria for MS.
18,19
Statement 9
Clinicians should offer DMTs to people with relapsing forms of MS with recent clinical relapses or MRI activity (Level B).
Starting: Recommendation 10 Rationale
Lack of adherence to treatment of chronic diseases is a wide-ranging problem. The result of poor adherence is reduced effectiveness and increased health care costs. [20] [21] [22] [23] [24] [25] Regular interactions and assessments by clinicians facilitate prompt identification and treatment of AEs, increased tolerability of the medication, and safety monitoring. 7, 25 Some DMTs for MS have specific risk evaluation and mitigation strategies (REMS) with recommendations for follow-up frequency.
26-29
Statement 10a
Clinicians should monitor for medication adherence, AEs, tolerability, safety, and effectiveness of the therapy in people with MS on DMTs (Level B).
Statement 10b
Clinicians should follow up either annually or according to medication-specific REMS in people with MS on DMTs (Level B).
Starting: Recommendation 11
Rationale DMTs have potential risks in pregnant women 30 to varying degrees. Discussing pregnancy with women with MS before initiating DMT is a part of good clinical practice. If women with MS are planning pregnancy soon, DMT use may need to be deferred until after pregnancy. 31 In addition, because DMTs vary in terms of pregnancy risks, 30 DMT choice may be influenced by plans for pregnancy.
Statement 11
Clinicians should monitor the reproductive plans of women with MS and counsel regarding reproductive risks and use of birth control during DMT use in women of childbearing potential who have MS (Level B).
Starting: Recommendation 12
Rationale Chemotherapy, such as cyclophosphamide, may affect male fertility. 32 With teriflunomide treatment, there may be a risk of teratogenicity from male sperm, which could last for 2 years after treatment cessation if the patient is not treated with chelation therapy. 33 
Statement 12
Clinicians should counsel men with MS on their reproductive plans regarding treatment implications before initiating treatment with teriflunomide or cyclophosphamide (Level B).
Starting: Recommendation 13
Rationale Post approval of mitoxantrone, new evidence has shown a high risk of cardiomyopathy, ovarian failure, male infertility, chromosomal aberrations, and promyelocytic leukemia [34] [35] [36] [37] associated with mitoxantrone use. Other effective medications with lower risk, which were unavailable at the time of US Food and Drug Administration (FDA) approval of mitoxantrone, are now available for treating MS.
Statement 13
Because of the high frequency of severe AEs, clinicians should not prescribe mitoxantrone to people with MS unless the potential therapeutic benefits greatly outweigh the risks (Level B).
Starting: Recommendation 14
Rationale MS is a heterogeneous disease and is characterized by highly variable degrees of disease activity in the relapsing phase and by varying rates of worsening during the progressive phases. 38, 39 Definitions of highly active MS vary and can include measures of relapsing activity and MRI markers of disease activity, such as numbers of gadolinium-enhanced lesions. 40,e1 Subgroup analyses from phase III pivotal trials of alemtuzumab, fingolimod, and natalizumab showed a reduction in relapses and MRI measures in people with MS with highly active disease.
e2-e4 Compared with interferon-β (IFN-β) therapy, treatment with these therapies resulted in more favorable outcomes in the subgroup of people with MS with highly active disease.
e5-e8 However, the risks and benefits of each treatment strategy need to be considered on a patientby-patient basis.
Statement 14
Clinicians should prescribe alemtuzumab, fingolimod, or natalizumab for people with MS with highly active MS (Level B).
Starting: Recommendation 15
Rationale DMTs should be available to all people with relapsing forms of MS. Because of disparities in health care provision in different settings, e9 there may be situations where approved DMTs are not available to an individual. In these situations, DMTs may be obtained with support from the pharmaceutical industry or from organizations, such as the National Organization of Rare Diseases, county organizations, or government organizations. If such support is unavailable, certain lower cost medications may become a choice for care. Azathioprine has mixed results and evidence for which confidence is low to support efficacy in relapsing forms of MS. Cladribine has evidence of benefit for both the oral and parenteral formulations, but currently only the parenteral formulations are available.
Statement 15a
Clinicians may direct people with MS who are candidates for DMTs to support programs (Level C).
Statement 15b
Clinicians may recommend azathioprine or cladribine for people with relapsing forms of MS who do not have access to approved DMTs (Level C).
Starting: Recommendation 16 Rationale
People with MS with a positive John Cunningham virus (JCV) antibody test have a higher risk of developing progressive multifocal leukoencephalopathy (PML) while using natalizumab, particularly people with MS who have been treated for more than 2 years or have had prior immunosuppressive treatment. There are now other highly effective treatments that may be used that have not been shown to have a similar PML risk. The PML risk increases with the level of anti-JCV antibody response (index). For example, in those using natalizumab for 25-36 months with no prior use of immunosuppressants, the PML risk is 0.2 per 1,000 in those with an index of 0.9 or less, 0.3 per 1,000 in those with an index of 0.9-1.5, and 3 per 1,000 in those with an index greater than 1.5. Further data on risk assessment is likely to become available over time to help inform treatment decisions in this area.
Statement 16
Clinicians may initiate natalizumab treatment in people with MS with positive anti-JCV antibody indexes above 0.9 only when there is a reasonable chance of benefit compared with the low but serious risk of PML (Level C).
Starting: Recommendation 17 Rationale
Ocrelizumab is the only DMT shown to alter disease progression in individuals with primary progressive MS (PPMS) who are ambulatory. The randomized controlled trial (RCT) of rituximab in PPMS was promising but inconclusive. Although RCTs of fingolimod, glatiramer acetate, and IFN-β-1b failed to demonstrate an effect on disability progression in individuals with PPMS, significant effects on MRI measures of disease activity were found with all 3 treatments.
e11-e13
Clinical trials have not evaluated the benefits of DMT in individuals with PPMS who are nonambulatory with respect to other clinically relevant domains, including vision, cognition, and upper limb function.
Statement 17
Clinicians should offer ocrelizumab to people with PPMS who are likely to benefit from this therapy unless there are risks of treatment that outweigh the benefits (Level B).
Switching DMT: Recommendations
Switching: Recommendation 1
Rationale
Ongoing disease activity, measured either by clinical relapses or new MRI-detected lesions (including unequivocally new T2 or new gadolinium-enhanced lesions), could lead to physical or cognitive worsening over time.
e14−e17 Now that several DMTs are available and have demonstrated efficacy for the prevention of clinical relapses and new MRI-detected lesions, physicians and people with MS often face the decision of switching from one DMT to another because of a perceived lack of efficacy. Such lack of response to a DMT has been difficult to define, as most people with MS are not free of all disease activity; investigators have considered using the number of clinical attacks or new MRI-detected lesions in the preceding 12 months to define lack of response. e15,e17 DMTs take a variable amount of time to become clinically active, and new lesion formation may occur after initiation but before the time of full efficacy, confounding interpretation of follow-up MRI scans.
e5,e6,e18−e21 Consequently, many clinicians obtain new baseline MRI 3-6 months after initiating DMTs to monitor from a treated baseline. e22 The optimal interval for ongoing monitoring is uncertain, as short-term stability as evidenced by clinical and MRI criteria may not consistently predict long-term stability. In addition, because of different mechanisms of activity among the DMTs, monitoring strategies may vary.
Statement 1a
Clinicians should monitor MRI disease activity from the clinical onset of disease to detect the accumulation of new lesions in order to inform treatment decisions in people with MS using DMTs (Level B).
Statement 1b
Clinicians should recognize that relapses or new MRIdetected lesions may develop after initiation of a DMT and before the treatment becomes effective in people with MS who are using DMTs (Level B).
Statement 1c
Clinicians should discuss switching from one DMT to another in people with MS who have been using a DMT long enough for the treatment to take full effect and are adherent to their therapy when they experience 1 or more relapses, 2 or more unequivocally new MRI-detected lesions, or increased disability on examination, over a 1-year period of using a DMT (Level B).
Switching: Recommendation 2 Rationale
None of the available DMTs is completely effective against relapses and MRI activity. When a patient shows breakthrough disease activity (continued relapses, MRI activity), trying a medication with a different mechanism or efficacy profile may be beneficial. Although all possible clinical scenarios cannot be answered by drug trials, current evidence supports higher efficacy of alemtuzumab, natalizumab, fingolimod, and ocrelizumab compared with previously approved self-injectable DMTs. Tolerability and likelihood of adherence are other factors that are important in decisions about switching DMTs. Physician judgment and patient preferences are critical in this process.
Statement 2
Clinicians should evaluate the degree of disease activity, adherence, AE profiles, and mechanism of action of DMTs when switching DMTs in people with MS with breakthrough disease activity during DMT use (Level B).
Switching
: Recommendation 3 Rationale Multiple DMTs are available for MS treatment. Switching therapies may be appropriate in people with MS who are experiencing AEs or complications with a DMT. Adherence to injectable DMTs is often incomplete. e23 Injection fatigue (physical or emotional) or injection-related pain or discomfort may be a common reason for poor adherence.
Statement 3
Clinicians should discuss a change to noninjectable or less frequently injectable DMTs in people with MS who report intolerable discomfort with the injections or in those who report injection fatigue on injectable DMTs (Level B).
Switching: Recommendation 4 Rationale
Adherence to a DMT may also be affected by medication AEs. 13, 25 All DMTs have common AEs that may affect adherence (table e-2, links.lww.com/WNL/A376).
Statement 4a
Clinicians should inquire about medication AEs with people with MS who are taking a DMT and attempt to manage these AEs, as appropriate (Level B).
Statement 4b
Clinicians should discuss a medication switch with people with MS for whom these AEs negatively influence adherence (Level B).
Switching: Recommendation 5 Rationale
Persistent laboratory abnormalities, such as elevated liver enzymes and decreased white blood cell counts, may prompt a discussion about switching DMT (table e-2, links.lww.com/ WNL/A376).
Statement 5a
Clinicians should monitor laboratory abnormalities found on requisite laboratory surveillance (as outlined in the medication's package insert) in people with MS who are using a DMT (Level B).
Statement 5b
Clinicians should discuss switching DMT or reducing dosage or frequency (where there are data on different doses [e.g.,
Switching: Recommendation 6
Rationale PML is a serious safety concern e24 that may affect compliance and necessitate consideration of a treatment switch. The PML risk is estimated at 4 per 1,000 overall with natalizumab e25 ; however, the presence and index level of JCV antibodies, longer duration use, and prior immunosuppression increase PML risk with natalizumab even further.
e24 Recent updated risk estimates show that the risk of developing PML is small at antibody index values of 0.9 or less, and increases with index values greater than 1.5 in people with MS who have been treated with natalizumab for more than 2 years. 11 There are rare reports of PML with the use of both fingolimod and dimethyl fumarate.
e26-e29 There are reports of PML in people with MS who are HIV-negative and using rituximab for conditions other than MS.
e30 There is a potential risk of PML with ocrelizumab use, particularly with prior immunosuppressive therapies based on its similarity to other anti-CD20 antibodies.
e31
Statement 6a
Clinicians should counsel people with MS considering natalizumab, fingolimod, rituximab, ocrelizumab, and dimethyl fumarate about the PML risk associated with these agents (Level B).
Statement 6b
Clinicians should discuss switching to a DMT with a lower PML risk with people with MS taking natalizumab who are or become JCV antibody-positive, especially with an index of above 0.9 while on therapy (Level B).
Switching: Recommendation 7 Rationale
Immunosuppressive medications may increase the risk of opportunistic infection and malignancy, especially with prolonged use. These risks are often undefined with newer medication. Cases of cryptococcal infections have been reported with fingolimod use. e32 Herpes family virus infections have been reported with fingolimod and natalizumab use.
e33−e35 A potential increased risk of basal cell carcinoma was recently added to the fingolimod product label. 
Statement 7a
Clinicians should counsel that new DMTs without long-term safety data have an undefined risk of malignancy and infection for people with MS starting or using new DMTs (Level B).
Statement 7b
If a patient with MS develops a malignancy while using a DMT, clinicians should promptly discuss switching to an alternate DMT, especially for people with MS using azathioprine, methotrexate, mycophenolate, cyclophosphamide, fingolimod, teriflunomide, alemtuzumab, or dimethyl fumarate (Level B).
Statement 7c
People with MS with serious infections potentially linked to their DMT should switch DMTs (does not pertain to PML management in people with MS using DMT) (Level B).
Switching: Recommendation 8 Rationale
Neutralizing antibodies may be produced against natalizumab and have been associated with allergic reactions.
e36,e37 These antibodies may reduce the efficacy of the medication, especially if they are persistent.
Statement 8a
Clinicians should check for natalizumab antibodies in people with MS who have infusion reactions before subsequent infusions, or in people with MS who experience breakthrough disease activity with natalizumab use (Level B).
Statement 8b
Clinicians should switch DMTs in people with MS who have persistent natalizumab antibodies (Level B).
Switching: Recommendation 9 Rationale
People with MS taking natalizumab may discontinue natalizumab because of fear of PML risk or for pregnancy planning. Natalizumab discontinuation increases the risk of MRIdetected disease activity and MS relapse within 6 months of discontinuation, with some people with MS having an increase in disease activity above their baseline activity, referred to as rebound activity.
e38 Data are limited for assessing the appropriate choice of an alternate DMT after natalizumab discontinuation. There is evidence that initiating fingolimod 8-12 weeks after natalizumab discontinuation reduces new MRI-detected lesions compared with initiation 16 weeks after natalizumab discontinuation. Initiating fingolimod 8-12 weeks after natalizumab discontinuation increases the proportion of people with MS who are relapse free compared with initiation after 16 weeks.
e39,e40 Although RCT data are unavailable, retrospective cohort data suggest that switching from natalizumab to rituximab may result in lower rates of clinical and radiologic disease activity compared with switching to fingolimod. 
Statement 9a
Physicians must counsel people with MS considering natalizumab discontinuation that there is an increased risk of MS relapse or MRI-detected disease activity within 6 months of discontinuation (Level A).
Statement 9b
Physicians and people with MS choosing to switch from natalizumab to fingolimod should initiate treatment within 8-12 weeks after natalizumab discontinuation (for reasons other than pregnancy or pregnancy planning) to diminish the return of disease activity (Level B).
Switching: Recommendation 10 Rationale
Relapse risk is reduced during pregnancy and increases in the postpartum period.
e42 Pregnancy exposure to DMTs may pose potential risks to the fetus to varying degrees, which vary from severe malformations to no major increased risk of malformations. Risks of important early-life health outcomes such as infections, vaccination responses, asthma, and neurocognitive disorders are unknown. FDA-approved medications vary in terms of FDA recommendation for pregnancy (e.g., glatiramer acetate ["Instruct people with MS that if they are pregnant or plan to become pregnant while taking glatiramer acetate they should inform their physician"; "Women of childbearing potential should be advised to avoid becoming pregnant"] and teriflunomide ["Must be avoided during pregnancy"]). Each DMT has a separate FDA statement about pregnancy-associated risks (see individual package inserts and attached tables). Discussing these potential risks and how best to minimize them is a part of good clinical practice. The majority of human safety data for exposure to DMTs during pregnancy are derived from accidental exposure early in pregnancy. There is a paucity of safety information with second-and third-trimester exposure. 
Statement 10a
Clinicians should counsel women to stop their DMT before conception for planned pregnancies unless the risk of MS activity during pregnancy outweighs the risk associated with the specific DMT during pregnancy (Level B).
Statement 10b
Clinicians should discontinue DMTs during pregnancy if accidental exposure occurs, unless the risk of MS activity during pregnancy outweighs the risk associated with the specific DMT during pregnancy (Level B).
Statement 10c
Clinicians should not initiate DMTs during pregnancy unless the risk of MS activity during pregnancy outweighs the risk associated with the specific DMT during pregnancy (Level B).
Stopping DMT: Recommendations
Stopping: Recommendation 1
Rationale
No RCTs have directly addressed the question of whether, when, or why to discontinue DMTs in an individual with relapsing-remitting MS (RRMS) who has no evidence of relapses or disability progression and has stable brain imaging. The natural history of untreated RRMS is for relapses and disability accumulation to occur. Early studies suggest that most individuals with RRMS ultimately advance to secondary progressive MS (SPMS) if observed for long enough intervals, although disease course is highly variable.
e44 People with MS who are stable on DMTs may question the continued value of using DMTs. If people with MS on DMTs stop these medications, continued monitoring may show subclinical disease activity or relapse activity that would indicate a possible need for treatment resumption. In an RCT of 175 individuals taking natalizumab who had been relapse free for 1 year and had no gadolinium-enhanced lesions on MRI, participants were randomized to continue natalizumab use, switch to placebo, or switch to other therapies. Relapses occurred in 4% of those continuing natalizumab use and in 15%-29% of those in other treatment arms over 24 weeks. An observational study comparing outcomes in individuals who did or did not stop DMT after a period of at least 5 years without relapses found a similar risk of relapses between the groups but an increased risk of disability progression among those who stopped DMT. Younger age and lower Expanded Disability Status Scale (EDSS) scores were significant predictors of relapse (clinical or MRI) after treatment discontinuation. People with MS who are on DMTs with no evidence of ongoing disease activity may be benefiting from their DMT with disease suppression. There are no biological markers of medication efficacy that can guide decision-making in this area.
Statement 1a
In people with RRMS who are stable on DMT and want to discontinue therapy, clinicians should counsel people regarding the need for ongoing follow-up and periodic reevaluation of the decision to discontinue DMT (Level B).
Statement 1b
Clinicians should advocate that people with MS who are stable (that is, no relapses, no disability progression, stable imaging) on DMT should continue their current DMT unless the patient and physician decide a trial off therapy is warranted (Level B).
Stopping: Recommendation 2 Rationale
People with SPMS who have relapses or active MRI-detected new lesion formation benefit from DMT. In people with SPMS who are ambulatory with or without assistance, IFN-β reduces the risk of relapse but does not delay disability progression as measured by the EDSS, a measure that emphasizes ambulation. No RCTs have directly addressed the question of whether or when to discontinue DMTs in people with SPMS. Clinical trials have not evaluated the benefits of DMT in individuals with SPMS who are nonambulatory with respect to other clinically relevant domains, including vision, cognition, and upper limb function. Relapses are associated with more rapid disability progression in SPMS but tend to occur in those at younger ages (younger than 55 years) and earlier in the disease course.
e45,e46 Among individuals with SPMS (those with and those without clinical relapses) for at least 2 years at the time of treatment withdrawal, an EDSS of 6 or greater was associated with a 50% lower risk of relapses or MRI-detected activity after treatment discontinuation. The benefits of therapy should outweigh the risks. The use of ineffective therapy may pose harms to the affected individual, society, and the health system.
Statement 2a
Clinicians should assess the likelihood of future relapse in individuals with SPMS by assessing patient age, disease duration, relapse history, and MRI-detected activity (e.g., frequency, severity, time since most recent relapse or gadolinium-enhanced lesion) (Level B).
Statement 2b
Clinicians may advise discontinuation of DMT in people with SPMS who do not have ongoing relapses (or gadoliniumenhanced lesions on MRI activity) and have not been ambulatory (EDSS 7 or greater) for at least 2 years (Level C).
Stopping: Recommendation 3 Rationale
DMTs tested in people with CIS delay progression to MS onset. However, some people with CIS may not develop MS. e47 Risks of active relapsing disease activity are higher in younger people with CIS. 17,e48,e49 In the absence of disease activity, people with CIS who are on DMTs may question the value of continuing DMTs indefinitely. There remains a gap in knowledge about stopping DMTs in people with CIS. Discussing the risks of continuing DMTs vs the risks of their use being unnecessary as part of ongoing treatment is a part of good clinical practice.
Statement 3
Clinicians should review the associated risks of continuing DMTs vs those of stopping DMTs in people with CIS using DMTs who have not been diagnosed with MS (Level B).
Clinical context for all evidence
This practice guideline reflects the complexity of decisionmaking when considering initiating, switching, or stopping DMT use for MS. The guideline panel has striven to reflect a patient-centric approach incorporating assessment of attitudes, readiness to start or change DMTs, therapy adherence, patient-specific factors (e.g., comorbidities), and an ongoing discussion of DMT use in people with MS on DMTs. The panel reviewed both FDA-approved DMTs and medications that have been used off-label for which efficacy data may be analyzed. The panel engaged in a transparent process, including extensive public review of the initial protocol, questions considered in the systematic review, and an early version of the systematic review and recommendations.
No guideline of this complexity will satisfy all audiences. The panel recognizes that the field of MS treatment is rapidly changing and the recommendations presented here may require reanalysis in light of new directions in the field and new evidence pertaining to DMT use. Issues with generalizability of randomized trials to heterogeneous real-world populations and extrapolation of short-term outcomes limit some of the conclusions. The panel anticipates needing to update this guideline in the not-too-distant future.
Suggestions for future research
Future research carried out on the following suggested topics would greatly improve informed decision-making for DMT use for MS.
High-quality evidence is needed concerning the effect of DMT for MS on outcomes deemed important by clinicians and people with MS beyond standard trials outcomes.
DMT for MS comparative efficacy studies are needed with transparent reporting in different MS subpopulations.
Clinical trials are needed to evaluate DMT benefit in individuals with SPMS who are nonambulatory with respect to other clinically relevant domains.
Studies are needed to examine whether initial high-potency treatment early in the disease course, compared with other DMTs, improves long-term outcomes.
There is a need for studies comparing highly active DMTs for MS treatment and different DMTs for CIS treatment.
Studies are warranted to determine whether switching DMTs vs continuing a DMT, despite continued disease activity, results in improved long-term outcomes.
Continued research is urged to identify biomarkers that can predict DMT efficacy in different patient subpopulations.
More research is needed to minimize risk to the pregnant woman and her fetus. Particular concerns include determining when DMT for MS should be stopped before conception, whether some agents are safer than others, and which agents might be safe enough to continue through conception and pregnancy in people with MS with active disease. More data are needed examining the risk of return of disease activity during pregnancy or the postpartum period on the mother's long-term disability risk and quality of life with DMT discontinuation during preconception, early pregnancy, or lactation.
More studies are needed to inform decisions about the possibility of DMT discontinuation, and in which circumstance, if any, discontinuation poses little or no harm.
Trial designs such as pragmatic clinical trials in clinical populations are needed to address treatment variation.
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